ID RIR2B_HUMAN Reviewed; 351 AA. AC Q7LG56; B4E2N4; Q17R22; Q75PQ6; Q75PQ7; Q75PY8; Q75PY9; Q86YE3; Q9NPD6; AC Q9NTD8; Q9NUW3; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 197. DE RecName: Full=Ribonucleoside-diphosphate reductase subunit M2 B; DE EC=1.17.4.1; DE AltName: Full=TP53-inducible ribonucleotide reductase M2 B; DE AltName: Full=p53-inducible ribonucleotide reductase small subunit 2-like protein; DE Short=p53R2; GN Name=RRM2B; Synonyms=P53R2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, AND RP INDUCTION. RX PubMed=10716435; DOI=10.1038/35003506; RA Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., RA Takei Y., Nakamura Y.; RT "A ribonucleotide reductase gene involved in a p53-dependent cell-cycle RT checkpoint for DNA damage."; RL Nature 404:42-49(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5). RA Ugai H., Yokoyama K.K.; RT "Homo sapiens p53-inducible ribonucleotide reductase small subunit 2 RT splicing variants."; RL Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 1-351 (ISOFORM 6). RC TISSUE=Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, AND SUBUNIT. RX PubMed=11517226; DOI=10.1074/jbc.m106088200; RA Guittet O., Haakansson P., Voevodskaya N., Fridd S., Graeslund A., RA Arakawa H., Nakamura Y., Thelander L.; RT "Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro RT with the R1 protein, which is expressed both in resting cells in response RT to DNA damage and in proliferating cells."; RL J. Biol. Chem. 276:40647-40651(2001). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, AND VARIANT LEU-115. RX PubMed=11719458; RA Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., RA Arakawa H.; RT "p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle RT checkpoint."; RL Cancer Res. 61:8256-8262(2001). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH TP53 AND RRM1. RX PubMed=12615712; RA Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y.; RT "Wild-type p53 regulates human ribonucleotide reductase by protein-protein RT interaction with p53R2 as well as hRRM2 subunits."; RL Cancer Res. 63:980-986(2003). RN [12] RP TISSUE SPECIFICITY. RX PubMed=14583450; RA Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., Shih J., Hwu E.B., RA Luh F., Yen Y.; RT "The human ribonucleotide reductase subunit hRRM2 complements p53R2 in RT response to UV-induced DNA repair in cells with mutant p53."; RL Cancer Res. 63:6583-6594(2003). RN [13] RP CATALYTIC ACTIVITY, AND SUBUNIT. RX PubMed=16376858; DOI=10.1016/j.bbrc.2005.12.019; RA Qiu W., Zhou B., Darwish D., Shao J., Yen Y.; RT "Characterization of enzymatic properties of human ribonucleotide reductase RT holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits."; RL Biochem. Biophys. Res. Commun. 340:428-434(2006). RN [14] RP INVOLVEMENT IN PEOA5. RX PubMed=19664747; DOI=10.1016/j.ajhg.2009.07.009; RA Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., RA Suomalainen A.; RT "A heterozygous truncating mutation in RRM2B causes autosomal-dominant RT progressive external ophthalmoplegia with multiple mtDNA deletions."; RL Am. J. Hum. Genet. 85:290-295(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH IRON IONS, AND RP COFACTOR. RX PubMed=19728742; DOI=10.1021/bi9001425; RA Smith P., Zhou B., Ho N., Yuan Y.C., Su L., Tsai S.C., Yen Y.; RT "2.6 A X-ray crystal structure of human p53R2, a p53-inducible RT ribonucleotide reductase."; RL Biochemistry 48:11134-11141(2009). RN [17] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 20-322 IN COMPLEX WITH IRON IONS. RG Structural genomics consortium (SGC); RT "Human ribonucleotide reductase, subunit M2 B."; RL Submitted (FEB-2009) to the PDB data bank. RN [18] RP VARIANTS MTDPS8A ARG-64; GLU-85 DEL; GLY-194; LYS-194 AND PHE-236. RX PubMed=17486094; DOI=10.1038/ng2040; RA Bourdon A., Minai L., Serre V., Jais J.-P., Sarzi E., Aubert S., RA Chretien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., RA Munnich A., Roetig A.; RT "Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase RT (p53R2), causes severe mitochondrial DNA depletion."; RL Nat. Genet. 39:776-780(2007). RN [19] RP VARIANTS MTDPS8A SER-224; ILE-282 AND VAL-317. RX PubMed=18504129; DOI=10.1016/j.nmd.2008.04.006; RA Bornstein B., Area E., Flanigan K.M., Ganesh J., Jayakar P., Swoboda K.J., RA Coku J., Naini A., Shanske S., Tanji K., Hirano M., DiMauro S.; RT "Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene."; RL Neuromuscul. Disord. 18:453-459(2008). RN [20] RP VARIANTS MTDPS8B HIS-110 AND HIS-121. RX PubMed=19667227; DOI=10.1001/archneurol.2009.139; RA Shaibani A., Shchelochkov O.A., Zhang S., Katsonis P., Lichtarge O., RA Wong L.J., Shinawi M.; RT "Mitochondrial neurogastrointestinal encephalopathy due to mutations in RT RRM2B."; RL Arch. Neurol. 66:1028-1032(2009). RN [21] RP VARIANT SER-33. RX PubMed=26741492; DOI=10.1371/journal.pgen.1005679; RA Kohda M., Tokuzawa Y., Kishita Y., Nyuzuki H., Moriyama Y., Mizuno Y., RA Hirata T., Yatsuka Y., Yamashita-Sugahara Y., Nakachi Y., Kato H., RA Okuda A., Tamaru S., Borna N.N., Banshoya K., Aigaki T., Sato-Miyata Y., RA Ohnuma K., Suzuki T., Nagao A., Maehata H., Matsuda F., Higasa K., RA Nagasaki M., Yasuda J., Yamamoto M., Fushimi T., Shimura M., RA Kaiho-Ichimoto K., Harashima H., Yamazaki T., Mori M., Murayama K., RA Ohtake A., Okazaki Y.; RT "A comprehensive genomic analysis reveals the genetic landscape of RT mitochondrial respiratory chain complex deficiencies."; RL PLoS Genet. 12:E1005679-E1005679(2016). RN [22] RP VARIANT RCDFRD ASP-262, AND INVOLVEMENT IN RCDFRD. RX PubMed=32827185; DOI=10.1002/humu.24094; RA Roberts L., Julius S., Dawlat S., Yildiz S., Rebello G., Meldau S., RA Pillay K., Esterhuizen A., Vorster A., Benefeld G., da Rocha J., RA Beighton P., Sellars S.L., Thandrayen K., Pettifor J.M., Ramesar R.S.; RT "Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss RT caused by a mutation in RRM2B."; RL Hum. Mutat. 41:1871-1876(2020). CC -!- FUNCTION: Plays a pivotal role in cell survival by repairing damaged CC DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for CC DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free CC radical center required for catalysis. Forms an active ribonucleotide CC reductase (RNR) complex with RRM1 which is expressed both in resting CC and proliferating cells in response to DNA damage. CC {ECO:0000269|PubMed:10716435, ECO:0000269|PubMed:11517226, CC ECO:0000269|PubMed:11719458}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 2'-deoxyribonucleoside 5'-diphosphate + [thioredoxin]- CC disulfide + H2O = a ribonucleoside 5'-diphosphate + [thioredoxin]- CC dithiol; Xref=Rhea:RHEA:23252, Rhea:RHEA-COMP:10698, Rhea:RHEA- CC COMP:10700, ChEBI:CHEBI:15377, ChEBI:CHEBI:29950, ChEBI:CHEBI:50058, CC ChEBI:CHEBI:57930, ChEBI:CHEBI:73316; EC=1.17.4.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10014, CC ECO:0000269|PubMed:16376858}; CC -!- COFACTOR: CC Name=Fe cation; Xref=ChEBI:CHEBI:24875; CC Evidence={ECO:0000269|PubMed:19728742}; CC Note=Binds 2 iron ions per subunit. {ECO:0000269|PubMed:19728742}; CC -!- SUBUNIT: Heterotetramer with large (RRM1) subunit. Interacts with CC p53/TP53. Interacts with RRM1 in response to DNA damage. CC {ECO:0000269|PubMed:11517226, ECO:0000269|PubMed:12615712, CC ECO:0000269|PubMed:16376858, ECO:0000269|PubMed:19728742, CC ECO:0000269|Ref.17}. CC -!- INTERACTION: CC Q7LG56; Q13315: ATM; NbExp=3; IntAct=EBI-9009083, EBI-495465; CC Q7LG56; Q00987: MDM2; NbExp=2; IntAct=EBI-9009083, EBI-389668; CC Q7LG56; O43929: ORC4; NbExp=4; IntAct=EBI-9009083, EBI-374889; CC Q7LG56; Q9H4P4: RNF41; NbExp=3; IntAct=EBI-9009083, EBI-2130266; CC Q7LG56; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-9009083, EBI-9009083; CC Q7LG56-1; Q00987: MDM2; NbExp=2; IntAct=EBI-15741413, EBI-389668; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates from CC cytoplasm to nucleus in response to DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q7LG56-1; Sequence=Displayed; CC Name=2; Synonyms=Long form; CC IsoId=Q7LG56-2; Sequence=VSP_017670; CC Name=3; Synonyms=Short form gamma; CC IsoId=Q7LG56-3; Sequence=VSP_017669; CC Name=4; Synonyms=Short form beta; CC IsoId=Q7LG56-4; Sequence=VSP_017668; CC Name=5; Synonyms=Short form; CC IsoId=Q7LG56-5; Sequence=VSP_017671, VSP_017672; CC Name=6; CC IsoId=Q7LG56-6; Sequence=VSP_053585; CC -!- TISSUE SPECIFICITY: Widely expressed at a high level in skeletal muscle CC and at a weak level in thymus. Expressed in epithelial dysplasias and CC squamous cell carcinoma. {ECO:0000269|PubMed:14583450}. CC -!- INDUCTION: In response to DNA damage in a wild-type p53/TP53-dependent CC manner. {ECO:0000269|PubMed:10716435}. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8A (MTDPS8A) CC [MIM:612075]: A disorder due to mitochondrial dysfunction characterized CC by various combinations of neonatal hypotonia, neurological CC deterioration, respiratory distress, lactic acidosis, and renal CC tubulopathy. {ECO:0000269|PubMed:17486094, CC ECO:0000269|PubMed:18504129}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8B (MTDPS8B) CC [MIM:612075]: A disease due to mitochondrial dysfunction and CC characterized by ophthalmoplegia, ptosis, gastrointestinal dysmotility, CC cachexia, peripheral neuropathy. {ECO:0000269|PubMed:19667227}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA CC deletions, autosomal dominant, 5 (PEOA5) [MIM:613077]: A disorder CC characterized by progressive weakness of ocular muscles and levator CC muscle of the upper eyelid. In a minority of cases, it is associated CC with skeletal myopathy, which predominantly involves axial or proximal CC muscles and which causes abnormal fatigability and even permanent CC muscle weakness. Ragged-red fibers and atrophy are found on muscle CC biopsy. A large proportion of chronic ophthalmoplegias are associated CC with other symptoms, leading to a multisystemic pattern of this CC disease. Additional symptoms are variable, and may include cataracts, CC hearing loss, sensory axonal neuropathy, ataxia, depression, CC hypogonadism, and parkinsonism. {ECO:0000269|PubMed:19664747}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Rod-cone dystrophy, sensorineural deafness, and Fanconi-type CC renal dysfunction (RCDFRD) [MIM:268315]: An autosomal recessive disease CC characterized by visual impairment due to rod-cone dystrophy, CC sensorineural hearing loss, and Fanconi-type renal dysfunction CC resulting in rickets-like skeletal changes. Death may occur in CC childhood or young adulthood due to renal failure. Disease onset is CC before age 5 years. {ECO:0000269|PubMed:32827185}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the ribonucleoside diphosphate reductase small CC chain family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65196.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=EAW91842.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB036063; BAA92434.1; -; mRNA. DR EMBL; AB036532; BAA92493.1; -; Genomic_DNA. DR EMBL; AB163437; BAD11774.1; -; mRNA. DR EMBL; AB163438; BAD11775.1; -; mRNA. DR EMBL; AB166669; BAD12265.1; -; mRNA. DR EMBL; AB166670; BAD12266.1; -; mRNA. DR EMBL; AB166671; BAD12267.1; -; mRNA. DR EMBL; AK001965; BAA92005.1; -; mRNA. DR EMBL; AK304354; BAG65196.1; ALT_INIT; mRNA. DR EMBL; DC308409; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL137348; CAB70703.2; -; mRNA. DR EMBL; DQ027001; AAY29059.1; -; Genomic_DNA. DR EMBL; AP001328; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP002907; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW91842.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC042468; AAH42468.1; -; mRNA. DR EMBL; BC108261; AAI08262.1; -; mRNA. DR EMBL; BC117496; AAI17497.1; -; mRNA. DR EMBL; BC130628; AAI30629.1; -; mRNA. DR CCDS; CCDS34932.1; -. [Q7LG56-1] DR CCDS; CCDS55267.1; -. [Q7LG56-2] DR PIR; T46249; T46249. DR RefSeq; NP_001165948.1; NM_001172477.1. [Q7LG56-6] DR RefSeq; NP_001165949.1; NM_001172478.2. [Q7LG56-2] DR RefSeq; NP_056528.2; NM_015713.4. [Q7LG56-1] DR PDB; 2VUX; X-ray; 2.80 A; A/B=20-322. DR PDB; 3HF1; X-ray; 2.60 A; A/B=1-351. DR PDB; 4DJN; X-ray; 2.20 A; A/B=13-322. DR PDBsum; 2VUX; -. DR PDBsum; 3HF1; -. DR PDBsum; 4DJN; -. DR AlphaFoldDB; Q7LG56; -. DR SMR; Q7LG56; -. DR BioGRID; 119071; 74. DR ComplexPortal; CPX-369; Ribonucleoside-diphosphate reductase RR1 complex, RRM2B variant. DR CORUM; Q7LG56; -. DR DIP; DIP-24264N; -. DR DIP; DIP-48627N; -. DR FunCoup; Q7LG56; 2091. DR IntAct; Q7LG56; 34. DR STRING; 9606.ENSP00000251810; -. DR BindingDB; Q7LG56; -. DR ChEMBL; CHEMBL3301398; -. DR DrugBank; DB00242; Cladribine. DR DrugBank; DB00631; Clofarabine. DR DrugBank; DB12948; Didox. DR GlyGen; Q7LG56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q7LG56; -. DR PhosphoSitePlus; Q7LG56; -. DR BioMuta; RRM2B; -. DR DMDM; 74727333; -. DR jPOST; Q7LG56; -. DR MassIVE; Q7LG56; -. DR PaxDb; 9606-ENSP00000251810; -. DR PeptideAtlas; Q7LG56; -. DR ProteomicsDB; 5837; -. DR ProteomicsDB; 68860; -. [Q7LG56-1] DR ProteomicsDB; 68861; -. [Q7LG56-2] DR ProteomicsDB; 68862; -. [Q7LG56-3] DR ProteomicsDB; 68863; -. [Q7LG56-4] DR ProteomicsDB; 68864; -. [Q7LG56-5] DR Pumba; Q7LG56; -. DR Antibodypedia; 3483; 343 antibodies from 38 providers. DR DNASU; 50484; -. DR Ensembl; ENST00000251810.8; ENSP00000251810.3; ENSG00000048392.14. [Q7LG56-1] DR Ensembl; ENST00000395912.6; ENSP00000379248.2; ENSG00000048392.14. [Q7LG56-2] DR Ensembl; ENST00000519317.5; ENSP00000430641.1; ENSG00000048392.14. [Q7LG56-3] DR Ensembl; ENST00000519962.5; ENSP00000429140.1; ENSG00000048392.14. [Q7LG56-4] DR Ensembl; ENST00000522394.1; ENSP00000429578.1; ENSG00000048392.14. [Q7LG56-5] DR GeneID; 50484; -. DR KEGG; hsa:50484; -. DR MANE-Select; ENST00000251810.8; ENSP00000251810.3; NM_015713.5; NP_056528.2. DR UCSC; uc003ykn.4; human. [Q7LG56-1] DR AGR; HGNC:17296; -. DR ClinPGx; PA34866; -. DR CTD; 50484; -. DR DisGeNET; 50484; -. DR GeneCards; RRM2B; -. DR GeneReviews; RRM2B; -. DR HGNC; HGNC:17296; RRM2B. DR HPA; ENSG00000048392; Low tissue specificity. DR MalaCards; RRM2B; -. DR MIM; 268315; phenotype. DR MIM; 604712; gene. DR MIM; 612075; phenotype. DR MIM; 613077; phenotype. DR OpenTargets; ENSG00000048392; -. DR Orphanet; 329336; Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy. DR Orphanet; 254892; Autosomal dominant progressive external ophthalmoplegia. DR Orphanet; 480; Kearns-Sayre syndrome. DR Orphanet; 255235; Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy. DR Orphanet; 298; Mitochondrial neurogastrointestinal encephalomyopathy. DR VEuPathDB; HostDB:ENSG00000048392; -. DR eggNOG; KOG1567; Eukaryota. DR GeneTree; ENSGT00390000013305; -. DR HOGENOM; CLU_035339_2_0_1; -. DR InParanoid; Q7LG56; -. DR OMA; LEPMFLG; -. DR OrthoDB; 10248373at2759; -. DR PAN-GO; Q7LG56; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q7LG56; -. DR BRENDA; 1.17.4.1; 2681. DR PathwayCommons; Q7LG56; -. DR Reactome; R-HSA-499943; Interconversion of nucleotide di- and triphosphates. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR SignaLink; Q7LG56; -. DR SIGNOR; Q7LG56; -. DR Agora; ENSG00000048392; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 50484; 17 hits in 1170 CRISPR screens. DR ChiTaRS; RRM2B; human. DR EvolutionaryTrace; Q7LG56; -. DR GeneWiki; RRM2B; -. DR GenomeRNAi; 50484; -. DR Pharos; Q7LG56; Tbio. DR PRO; PR:Q7LG56; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q7LG56; protein. DR Bgee; ENSG00000048392; Expressed in secondary oocyte and 188 other cell types or tissues. DR ExpressionAtlas; Q7LG56; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:GOC. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005971; C:ribonucleoside-diphosphate reductase complex; ISS:ComplexPortal. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004748; F:ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor; IBA:GO_Central. DR GO; GO:0009265; P:2'-deoxyribonucleotide biosynthetic process; IDA:ComplexPortal. DR GO; GO:0009200; P:deoxyribonucleoside triphosphate metabolic process; IEA:Ensembl. DR GO; GO:0009263; P:deoxyribonucleotide biosynthetic process; IBA:GO_Central. DR GO; GO:0006281; P:DNA repair; IDA:ComplexPortal. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; NAS:ComplexPortal. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0006264; P:mitochondrial DNA replication; IMP:ComplexPortal. DR GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0070318; P:positive regulation of G0 to G1 transition; IDA:ComplexPortal. DR GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IDA:ComplexPortal. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0014075; P:response to amine; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl. DR GO; GO:0009185; P:ribonucleoside diphosphate metabolic process; IDA:ComplexPortal. DR CDD; cd01049; RNRR2; 1. DR FunFam; 1.10.620.20:FF:000004; Ribonucleoside-diphosphate reductase subunit M2 B; 1. DR Gene3D; 1.10.620.20; Ribonucleotide Reductase, subunit A; 1. DR InterPro; IPR009078; Ferritin-like_SF. DR InterPro; IPR012348; RNR-like. DR InterPro; IPR033909; RNR_small. DR InterPro; IPR030475; RNR_small_AS. DR InterPro; IPR000358; RNR_small_fam. DR PANTHER; PTHR23409; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SMALL CHAIN; 1. DR PANTHER; PTHR23409:SF19; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SUBUNIT M2 B; 1. DR Pfam; PF00268; Ribonuc_red_sm; 1. DR SUPFAM; SSF47240; Ferritin-like; 1. DR PROSITE; PS00368; RIBORED_SMALL; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Deafness; KW Deoxyribonucleotide synthesis; Disease variant; DNA damage; DNA repair; KW Iron; Metal-binding; Neuropathy; Nucleus; Oxidoreductase; KW Primary mitochondrial disease; Progressive external ophthalmoplegia; KW Proteomics identification; Reference proteome. FT CHAIN 1..351 FT /note="Ribonucleoside-diphosphate reductase subunit M2 B" FT /id="PRO_0000228150" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU10014" FT BINDING 100 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 134 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 194 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 228 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 231 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT VAR_SEQ 1..16 FT /note="MGDPERPEAAGLDQDE -> MLLLRLPPHRSHASPLDCKLQDRCRKCYSPRS FT GQACPPALAAAWLRRCERRGGRPRGGRRKELTLGLRPARCSAPGPAKDDAWRPQAG FT (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_053585" FT VAR_SEQ 17..301 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017668" FT VAR_SEQ 17..228 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017669" FT VAR_SEQ 17..68 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017670" FT VAR_SEQ 42..43 FT /note="FV -> SF (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017671" FT VAR_SEQ 44..351 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017672" FT VARIANT 33 FT /note="P -> S (found in a patient with combined respiratory FT complex deficiencies, muscle weakness and hearing loss; FT uncertain significance; dbSNP:rs387906892)" FT /evidence="ECO:0000269|PubMed:26741492" FT /id="VAR_076280" FT VARIANT 64 FT /note="W -> R (in MTDPS8A; dbSNP:rs515726182)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046217" FT VARIANT 85 FT /note="Missing (in MTDPS8A; dbSNP:rs515726184)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046218" FT VARIANT 110 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607025)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065122" FT VARIANT 115 FT /note="V -> L (in colorectal adenocarcinomas cell line; FT loss of ribonucleotide reductase activity)" FT /evidence="ECO:0000269|PubMed:11719458" FT /id="VAR_025699" FT VARIANT 121 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607024)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065123" FT VARIANT 194 FT /note="E -> G (in MTDPS8A; dbSNP:rs515726191)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046219" FT VARIANT 194 FT /note="E -> K (in MTDPS8A; dbSNP:rs121918308)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046220" FT VARIANT 224 FT /note="I -> S (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726196)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046221" FT VARIANT 236 FT /note="C -> F (in MTDPS8A; dbSNP:rs121918309)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046222" FT VARIANT 262 FT /note="E -> D (in RCDFRD; dbSNP:rs1810682433)" FT /evidence="ECO:0000269|PubMed:32827185" FT /id="VAR_086956" FT VARIANT 282 FT /note="M -> I (in MTDPS8A; without tubulopathy; FT dbSNP:rs182614164)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046223" FT VARIANT 317 FT /note="L -> V (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726198)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046224" FT CONFLICT 277 FT /note="M -> V (in Ref. 3; BAA92005)" FT /evidence="ECO:0000305" FT HELIX 29..31 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 42..44 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 50..61 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 74..78 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 83..109 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 111..114 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 118..145 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 149..156 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 158..161 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 163..177 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 183..195 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 199..210 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 215..240 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 248..267 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 272..275 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 279..296 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 310..312 FT /evidence="ECO:0007829|PDB:4DJN" SQ SEQUENCE 351 AA; 40737 MW; 6D008687EEF40994 CRC64; MGDPERPEAA GLDQDERSSS DTNESEIKSN EEPLLRKSSR RFVIFPIQYP DIWKMYKQAQ ASFWTAEEVD LSKDLPHWNK LKADEKYFIS HILAFFAASD GIVNENLVER FSQEVQVPEA RCFYGFQILI ENVHSEMYSL LIDTYIRDPK KREFLFNAIE TMPYVKKKAD WALRWIADRK STFGERVVAF AAVEGVFFSG SFAAIFWLKK RGLMPGLTFS NELISRDEGL HCDFACLMFQ YLVNKPSEER VREIIVDAVK IEQEFLTEAL PVGLIGMNCI LMKQYIEFVA DRLLVELGFS KVFQAENPFD FMENISLEGK TNFFEKRVSE YQRFAVMAET TDNVFTLDAD F // ID RNZ2_HUMAN Reviewed; 826 AA. AC Q9BQ52; B4DPL9; Q6IA94; Q9HAS8; Q9HAS9; Q9NVT1; DT 16-JAN-2004, integrated into UniProtKB/Swiss-Prot. DT 16-JAN-2004, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Zinc phosphodiesterase ELAC protein 2; DE EC=3.1.26.11; DE AltName: Full=ElaC homolog protein 2; DE AltName: Full=Heredity prostate cancer protein 2; DE AltName: Full=Ribonuclease Z 2; DE Short=RNase Z 2; DE AltName: Full=tRNA 3 endonuclease 2; DE AltName: Full=tRNase Z 2; DE Flags: Precursor; GN Name=ELAC2; Synonyms=HPC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP HPC2 LEU-217; THR-541 AND HIS-781. RX PubMed=11175785; DOI=10.1038/84808; RA Tavtigian S.V., Simard J., Teng D.H.F., Abtin V., Baumgard M., Beck A., RA Camp N.J., Carillo A.R., Chen Y., Dayananth P., Desrochers M., Dumont M., RA Farnham J.M., Frank D., Frye C., Ghaffari S., Gupte J.S., Hu R., Iliev D., RA Janecki T., Kort E.N., Laity K.E., Leavitt A., Leblanc G., RA McArthur-Morrison J., Pederson A., Penn B., Peterson K.T., Reid J.E., RA Richards S., Schroeder M., Smith R., Snyder S.C., Swedlund B., Swensen J., RA Thomas A., Tranchant M., Woodland A.-M., Labrie F., Skolnick M.H., RA Neuhausen S., Rommens J., Cannon-Albright L.A.; RT "A candidate prostate cancer susceptibility gene at chromosome 17p."; RL Nat. Genet. 27:172-180(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4). RC TISSUE=Hippocampus, Liver, Teratocarcinoma, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ENZYME ACTIVITY, AND CHARACTERIZATION OF VARIANTS HPC2 LEU-217; THR-541 AND RP HIS-781. RX PubMed=12711671; DOI=10.1093/nar/gkg337; RA Takaku H., Minagawa A., Takagi M., Nashimoto M.; RT "A candidate prostate cancer susceptibility gene encodes tRNA 3' processing RT endoribonuclease."; RL Nucleic Acids Res. 31:2272-2278(2003). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [9] RP INTERACTION WITH PTCD1. RX PubMed=21857155; DOI=10.4161/cc.10.17.17060; RA Sanchez M.I., Mercer T.R., Davies S.M., Shearwood A.M., Nygard K.K., RA Richman T.R., Mattick J.S., Rackham O., Filipovska A.; RT "RNA processing in human mitochondria."; RL Cell Cycle 10:2904-2916(2011). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21593607; DOI=10.4161/rna.8.4.15393; RA Brzezniak L.K., Bijata M., Szczesny R.J., Stepien P.P.; RT "Involvement of human ELAC2 gene product in 3' end processing of RT mitochondrial tRNAs."; RL RNA Biol. 8:616-626(2011). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199; SER-208; SER-229; RP SER-618 AND SER-736, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=24703694; DOI=10.1016/j.cmet.2014.03.013; RA Bogenhagen D.F., Martin D.W., Koller A.; RT "Initial steps in RNA processing and ribosome assembly occur at RT mitochondrial DNA nucleoids."; RL Cell Metab. 19:618-629(2014). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-208 AND SER-212, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=10986046; DOI=10.1086/303096; RA Rebbeck T.R., Walker A.H., Zeigler-Johnson C., Weisburg S., Martin A.-M., RA Nathanson K.L., Wein A.J., Malkowicz S.B.; RT "Association of HPC2/ELAC2 genotypes and prostate cancer."; RL Am. J. Hum. Genet. 67:1014-1019(2000). RN [16] RP VARIANT HPC2 VAL-622. RX PubMed=11507049; RA Roekman A., Ikonen T., Mononen N., Autio V., Matikainen M.P., RA Koivisto P.A., Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer."; RL Cancer Res. 61:6038-6041(2001). RN [17] RP VARIANTS HPC2 GLN-211; LEU-217; ARG-487; THR-541 AND ARG-806. RX PubMed=11522646; RA Wang L., McDonnell S.K., Elkins D.A., Slager S.L., Christensen E., RA Marks A.F., Cunningham J.M., Peterson B.J., Jacobsen S.J., Cerhan J.R., RA Blute M.L., Schaid D.J., Thibodeau S.N.; RT "Role of HPC2/ELAC2 in hereditary prostate cancer."; RL Cancer Res. 61:6494-6499(2001). RN [18] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12522685; DOI=10.1007/s100380200099; RA Fujiwara H., Emi M., Nagai H., Nishimura T., Konishi N., Kubota Y., RA Ichikawa T., Takahashi S., Shuin T., Habuchi T., Ogawa O., Inoue K., RA Skolnick M.H., Swensen J., Camp N.J., Tavtigian S.V.; RT "Association of common missense changes in ELAC2 (HPC2) with prostate RT cancer in a Japanese case-control series."; RL J. Hum. Genet. 47:641-648(2002). RN [19] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12515253; DOI=10.1086/344516; RA Camp N.J., Tavtigian S.V.; RT "Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in RT ELAC2 (HPC2) and prostate cancer."; RL Am. J. Hum. Genet. 71:1475-1478(2002). RN [20] RP VARIANT LEU-627. RX PubMed=12949798; DOI=10.1002/ijc.11347; RA Takahashi H., Lu W., Watanabe M., Katoh T., Furusato M., Tsukino H., RA Nakao H., Sudo A., Suzuki H., Akakura K., Ikemoto I., Asano K., Ito T., RA Wakui S., Muto T., Hano H.; RT "Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic RT cancer risk in Japanese men."; RL Int. J. Cancer 107:224-228(2003). RN [21] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12783937; DOI=10.1093/jnci/95.11.818; RA Severi G., Giles G.G., Southey M.C., Tesoriero A., Tilley W., Neufing P., RA Morris H., English D.R., McCredie M.R., Boyle P., Hopper J.L.; RT "ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate RT cancer."; RL J. Natl. Cancer Inst. 95:818-824(2003). RN [22] RP VARIANT [LARGE SCALE ANALYSIS] HPC2 LEU-217. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). RN [23] RP VARIANTS COXPD17 LEU-154; PHE-423 AND ILE-520. RX PubMed=23849775; DOI=10.1016/j.ajhg.2013.06.006; RA Haack T.B., Kopajtich R., Freisinger P., Wieland T., Rorbach J., RA Nicholls T.J., Baruffini E., Walther A., Danhauser K., Zimmermann F.A., RA Husain R.A., Schum J., Mundy H., Ferrero I., Strom T.M., Meitinger T., RA Taylor R.W., Minczuk M., Mayr J.A., Prokisch H.; RT "ELAC2 mutations cause a mitochondrial RNA processing defect associated RT with hypertrophic cardiomyopathy."; RL Am. J. Hum. Genet. 93:211-223(2013). CC -!- FUNCTION: Zinc phosphodiesterase, which displays mitochondrial tRNA 3'- CC processing endonuclease activity. Involved in tRNA maturation, by CC removing a 3'-trailer from precursor tRNA (PubMed:21593607). Associates CC with mitochondrial DNA complexes at the nucleoids to initiate RNA CC processing and ribosome assembly (PubMed:24703694). CC {ECO:0000269|PubMed:21593607, ECO:0000269|PubMed:24703694}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Endonucleolytic cleavage of RNA, removing extra 3' nucleotides CC from tRNA precursor, generating 3' termini of tRNAs. A 3'-hydroxy CC group is left at the tRNA terminus and a 5'-phosphoryl group is left CC at the trailer molecule.; EC=3.1.26.11; CC Evidence={ECO:0000269|PubMed:12711671}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000305}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with PTCD1. {ECO:0000250, CC ECO:0000269|PubMed:21857155}. CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:21593607}. CC Mitochondrion matrix, mitochondrion nucleoid CC {ECO:0000269|PubMed:24703694}. Nucleus {ECO:0000269|PubMed:21593607}. CC Note=Mainly mitochondrial. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9BQ52-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BQ52-2; Sequence=VSP_009169, VSP_009171, VSP_009172; CC Name=3; CC IsoId=Q9BQ52-3; Sequence=VSP_009168, VSP_009170; CC Name=4; CC IsoId=Q9BQ52-4; Sequence=VSP_043449; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in heart, CC placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. CC Weakly expressed in brain, lung, spleen, thymus, prostate, small CC intestine, colon and leukocytes. {ECO:0000269|PubMed:11175785}. CC -!- DISEASE: Prostate cancer, hereditary, 2 (HPC2) [MIM:614731]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:10986046, CC ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11507049, CC ECO:0000269|PubMed:11522646, ECO:0000269|PubMed:12515253, CC ECO:0000269|PubMed:12522685, ECO:0000269|PubMed:12711671, CC ECO:0000269|PubMed:12783937, ECO:0000269|PubMed:15489334, CC ECO:0000269|PubMed:18987736, ECO:0000269|Ref.3}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Combined oxidative phosphorylation deficiency 17 (COXPD17) CC [MIM:615440]: An autosomal recessive disorder of mitochondrial CC dysfunction characterized by onset of severe hypertrophic CC cardiomyopathy in the first year of life. Other features include CC hypotonia, poor growth, lactic acidosis, and failure to thrive. The CC disorder may be fatal in early childhood. CC {ECO:0000269|PubMed:23849775}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the RNase Z family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40437/ELAC2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF304369; AAG24440.1; -; Genomic_DNA. DR EMBL; AF304370; AAG24441.1; -; mRNA. DR EMBL; AK001392; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK124838; BAC85964.1; -; mRNA. DR EMBL; AK125030; BAC86026.1; -; mRNA. DR EMBL; AK298397; BAG60631.1; -; mRNA. DR EMBL; CR457261; CAG33542.1; -; mRNA. DR EMBL; AC005277; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC001939; AAH01939.1; -; mRNA. DR EMBL; BC004158; AAH04158.1; -; mRNA. DR CCDS; CCDS11164.1; -. [Q9BQ52-1] DR CCDS; CCDS54093.1; -. [Q9BQ52-4] DR RefSeq; NP_001159434.1; NM_001165962.2. [Q9BQ52-4] DR RefSeq; NP_060597.4; NM_018127.6. [Q9BQ52-1] DR RefSeq; NP_776065.1; NM_173717.1. DR PDB; 8CBL; EM; 2.79 A; E=1-826. DR PDB; 8RR1; EM; 2.93 A; E=32-826. DR PDB; 8RR3; EM; 3.40 A; E=32-826. DR PDB; 8RR4; EM; 3.20 A; E=32-826. DR PDB; 8Z0P; EM; 3.10 A; A=1-826. DR PDB; 8Z1F; EM; 4.30 A; A=1-826. DR PDB; 8Z1G; EM; 3.70 A; A=1-826. DR PDB; 9EY0; EM; 2.78 A; E=31-826. DR PDB; 9EY1; EM; 2.90 A; E=31-826. DR PDB; 9EY2; EM; 2.96 A; E=31-826. DR PDBsum; 8CBL; -. DR PDBsum; 8RR1; -. DR PDBsum; 8RR3; -. DR PDBsum; 8RR4; -. DR PDBsum; 8Z0P; -. DR PDBsum; 8Z1F; -. DR PDBsum; 8Z1G; -. DR PDBsum; 9EY0; -. DR PDBsum; 9EY1; -. DR PDBsum; 9EY2; -. DR AlphaFoldDB; Q9BQ52; -. DR EMDB; EMD-16544; -. DR EMDB; EMD-19453; -. DR EMDB; EMD-19455; -. DR EMDB; EMD-19457; -. DR EMDB; EMD-39710; -. DR EMDB; EMD-39726; -. DR EMDB; EMD-39727; -. DR EMDB; EMD-50050; -. DR EMDB; EMD-50051; -. DR EMDB; EMD-50052; -. DR SMR; Q9BQ52; -. DR BioGRID; 121937; 198. DR ComplexPortal; CPX-2240; Mitochondrial RNase Z complex. DR FunCoup; Q9BQ52; 3637. DR IntAct; Q9BQ52; 55. DR MINT; Q9BQ52; -. DR STRING; 9606.ENSP00000337445; -. DR GlyGen; Q9BQ52; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BQ52; -. DR MetOSite; Q9BQ52; -. DR PhosphoSitePlus; Q9BQ52; -. DR SwissPalm; Q9BQ52; -. DR BioMuta; ELAC2; -. DR DMDM; 41017788; -. DR jPOST; Q9BQ52; -. DR MassIVE; Q9BQ52; -. DR PaxDb; 9606-ENSP00000337445; -. DR PeptideAtlas; Q9BQ52; -. DR ProteomicsDB; 78627; -. [Q9BQ52-1] DR ProteomicsDB; 78628; -. [Q9BQ52-2] DR ProteomicsDB; 78629; -. [Q9BQ52-3] DR ProteomicsDB; 78630; -. [Q9BQ52-4] DR Pumba; Q9BQ52; -. DR Antibodypedia; 13065; 203 antibodies from 30 providers. DR DNASU; 60528; -. DR Ensembl; ENST00000338034.9; ENSP00000337445.4; ENSG00000006744.20. [Q9BQ52-1] DR Ensembl; ENST00000426905.7; ENSP00000405223.3; ENSG00000006744.20. [Q9BQ52-4] DR GeneID; 60528; -. DR KEGG; hsa:60528; -. DR MANE-Select; ENST00000338034.9; ENSP00000337445.4; NM_018127.7; NP_060597.4. DR UCSC; uc002gnz.5; human. [Q9BQ52-1] DR AGR; HGNC:14198; -. DR ClinPGx; PA27739; -. DR CTD; 60528; -. DR DisGeNET; 60528; -. DR GeneCards; ELAC2; -. DR HGNC; HGNC:14198; ELAC2. DR HPA; ENSG00000006744; Low tissue specificity. DR MalaCards; ELAC2; -. DR MIM; 176807; phenotype. DR MIM; 605367; gene. DR MIM; 614731; phenotype. DR MIM; 615440; phenotype. DR OpenTargets; ENSG00000006744; -. DR Orphanet; 369913; Combined oxidative phosphorylation defect type 17. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000006744; -. DR eggNOG; KOG2121; Eukaryota. DR GeneTree; ENSGT00730000111191; -. DR HOGENOM; CLU_006220_2_0_1; -. DR InParanoid; Q9BQ52; -. DR OMA; INYICQL; -. DR OrthoDB; 527344at2759; -. DR PAN-GO; Q9BQ52; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9BQ52; -. DR BRENDA; 3.1.26.11; 2681. DR PathwayCommons; Q9BQ52; -. DR Reactome; R-HSA-6784531; tRNA processing in the nucleus. DR Reactome; R-HSA-6785470; tRNA processing in the mitochondrion. DR Reactome; R-HSA-8868766; rRNA processing in the mitochondrion. DR Reactome; R-HSA-9708296; tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis. DR SignaLink; Q9BQ52; -. DR Agora; ENSG00000006744; -. DR BioGRID-ORCS; 60528; 738 hits in 1175 CRISPR screens. DR CD-CODE; F701F3BC; PcG body. DR ChiTaRS; ELAC2; human. DR GeneWiki; ELAC2; -. DR GenomeRNAi; 60528; -. DR Pharos; Q9BQ52; Tbio. DR PRO; PR:Q9BQ52; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9BQ52; protein. DR Bgee; ENSG00000006744; Expressed in adrenal tissue and 202 other cell types or tissues. DR ExpressionAtlas; Q9BQ52; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; IDA:FlyBase. DR GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0042781; F:3'-tRNA processing endoribonuclease activity; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; TAS:Reactome. DR GO; GO:0004549; F:tRNA-specific ribonuclease activity; EXP:Reactome. DR GO; GO:1990180; P:mitochondrial tRNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0090646; P:mitochondrial tRNA processing; TAS:Reactome. DR GO; GO:0042780; P:tRNA 3'-end processing; TAS:Reactome. DR GO; GO:0016078; P:tRNA decay; TAS:Reactome. DR CDD; cd07718; RNaseZ_ELAC1_ELAC2-C-term-like_MBL-fold; 1. DR CDD; cd16296; RNaseZ_ELAC2-N-term-like_MBL-fold; 1. DR FunFam; 3.60.15.10:FF:000014; Zinc phosphodiesterase ELAC protein 2; 1. DR Gene3D; 3.60.15.10; Ribonuclease Z/Hydroxyacylglutathione hydrolase-like; 2. DR InterPro; IPR036866; RibonucZ/Hydroxyglut_hydro. DR InterPro; IPR047151; RNZ2-like. DR InterPro; IPR027794; tRNase_Z_dom. DR PANTHER; PTHR12553; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR PANTHER; PTHR12553:SF49; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR Pfam; PF23023; Anti-Pycsar_Apyc1; 1. DR Pfam; PF13691; Lactamase_B_4; 1. DR SUPFAM; SSF56281; Metallo-hydrolase/oxidoreductase; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Endonuclease; KW Hydrolase; Metal-binding; Mitochondrion; Mitochondrion nucleoid; Nuclease; KW Nucleus; Phosphoprotein; Primary mitochondrial disease; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Transit peptide; tRNA processing; Zinc. FT TRANSIT 1..16 FT /note="Mitochondrion" FT /evidence="ECO:0000255" FT CHAIN 17..826 FT /note="Zinc phosphodiesterase ELAC protein 2" FT /id="PRO_0000155828" FT REGION 16..51 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 188..231 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 798..826 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 27..38 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 208..224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 808..820 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 199 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 208 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 212 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 618 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 736 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..372 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009168" FT VAR_SEQ 1..94 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009169" FT VAR_SEQ 188..227 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043449" FT VAR_SEQ 373..406 FT /note="NCASVHNLRSHKIQTQLNLIHPDIFPLLTSFRCK -> MRTVPQFTTFAATR FT FKPSSTSSTRTSSPCSPVSA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009170" FT VAR_SEQ 554..595 FT /note="GLPSILLQRERALASLGKPLHPLLVVAPNQLKAWLQQYHNQC -> VSVGLD FT HKAGAWRRHCHVELALWLRLFLRFQTCPELLLLISG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009171" FT VAR_SEQ 596..826 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009172" FT VARIANT 52 FT /note="S -> F (in dbSNP:rs9895963)" FT /id="VAR_038210" FT VARIANT 154 FT /note="F -> L (in COXPD17; dbSNP:rs397515465)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070844" FT VARIANT 211 FT /note="R -> Q (in HPC2; dbSNP:rs148419785)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017425" FT VARIANT 217 FT /note="S -> L (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs4792311)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:18987736, FT ECO:0000269|Ref.3" FT /id="VAR_017426" FT VARIANT 423 FT /note="L -> F (in COXPD17; dbSNP:rs397515466)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070845" FT VARIANT 436 FT /note="D -> N (in dbSNP:rs3760317)" FT /id="VAR_038211" FT VARIANT 487 FT /note="G -> R (in HPC2; dbSNP:rs752234492)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017427" FT VARIANT 520 FT /note="T -> I (in COXPD17; dbSNP:rs397515463)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070846" FT VARIANT 541 FT /note="A -> T (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs5030739)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937" FT /id="VAR_017428" FT VARIANT 622 FT /note="E -> V (in HPC2; higher frequency in prostate cancer FT cases; dbSNP:rs119484087)" FT /evidence="ECO:0000269|PubMed:11507049" FT /id="VAR_017429" FT VARIANT 627 FT /note="S -> L (in dbSNP:rs78105154)" FT /evidence="ECO:0000269|PubMed:12949798" FT /id="VAR_017430" FT VARIANT 781 FT /note="R -> H (in HPC2; does not affect the enzymatic FT activity; dbSNP:rs119484086)" FT /evidence="ECO:0000269|PubMed:11175785, FT ECO:0000269|PubMed:12711671" FT /id="VAR_017431" FT VARIANT 806 FT /note="G -> R (in HPC2; dbSNP:rs770669443)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017432" FT CONFLICT 165 FT /note="V -> M (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="Missing (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 592 FT /note="H -> Y (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="F -> L (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 58..65 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 68..70 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 72..80 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 91..97 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 107..109 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 111..114 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 121..131 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 134..141 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 144..155 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 161..167 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 176..186 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 239..247 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 256..262 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 268..270 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 272..279 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 293..296 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 305..310 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 317..321 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 324..330 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 338..343 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 346..349 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 352..360 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 365..369 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 380..392 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 394..396 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 416..418 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 424..429 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 432..434 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 443..451 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 453..455 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 456..468 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 481..487 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 489..492 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8Z0P" FT STRAND 499..507 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 510..514 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 520..528 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 529..531 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 532..537 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 539..543 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8Z0P" FT HELIX 549..552 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 555..569 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 576..580 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 584..594 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 602..608 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 619..632 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 634..639 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 643..647 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 651..655 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 660..663 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 671..676 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:8RR1" FT HELIX 694..700 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 705..715 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 720..723 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 740..742 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 743..745 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 754..763 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 764..770 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 772..790 FT /evidence="ECO:0007829|PDB:9EY0" SQ SEQUENCE 826 AA; 92219 MW; 4AE701C755EC7339 CRC64; MWALCSLLRS AAGRTMSQGR TISQAPARRE RPRKDPLRHL RTREKRGPSG CSGGPNTVYL QVVAAGSRDS GAALYVFSEF NRYLFNCGEG VQRLMQEHKL KVARLDNIFL TRMHWSNVGG LSGMILTLKE TGLPKCVLSG PPQLEKYLEA IKIFSGPLKG IELAVRPHSA PEYEDETMTV YQIPIHSEQR RGKHQPWQSP ERPLSRLSPE RSSDSESNEN EPHLPHGVSQ RRGVRDSSLV VAFICKLHLK RGNFLVLKAK EMGLPVGTAA IAPIIAAVKD GKSITHEGRE ILAEELCTPP DPGAAFVVVE CPDESFIQPI CENATFQRYQ GKADAPVALV VHMAPASVLV DSRYQQWMER FGPDTQHLVL NENCASVHNL RSHKIQTQLN LIHPDIFPLL TSFRCKKEGP TLSVPMVQGE CLLKYQLRPR REWQRDAIIT CNPEEFIVEA LQLPNFQQSV QEYRRSAQDG PAPAEKRSQY PEIIFLGTGS AIPMKIRNVS ATLVNISPDT SLLLDCGEGT FGQLCRHYGD QVDRVLGTLA AVFVSHLHAD HHTGLPSILL QRERALASLG KPLHPLLVVA PNQLKAWLQQ YHNQCQEVLH HISMIPAKCL QEGAEISSPA VERLISSLLR TCDLEEFQTC LVRHCKHAFG CALVHTSGWK VVYSGDTMPC EALVRMGKDA TLLIHEATLE DGLEEEAVEK THSTTSQAIS VGMRMNAEFI MLNHFSQRYA KVPLFSPNFS EKVGVAFDHM KVCFGDFPTM PKLIPPLKAL FAGDIEEMEE RREKRELRQV RAALLSRELA GGLEDGEPQQ KRAHTEEPQA KKVRAQ //